

Human Kallikrein 2/KLK2 Protein (active form)



Cat. No. KLK-HM002


Description	
Source	Recombinant Human Kallikrein 2/KLK2 Protein (active form) is expressed from HEK293 without tag. It contains Ile25-Pro261.
Accession	P20151-1
Molecular Weight	The protein has a predicted MW of 26.15 kDa. Due to glycosylation, the protein migrates to 28-35 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE

Formulation and Storage	
Formulation	Lyophilized from 0.22 µm filtered solution in 20mM Tris, 150mM NaCl, 8% trehalose, 0.05% Brij-35, 5mM Benzamidine (pH 8.0).
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
Kallikrein-related peptidase 2 (KLK2) is a serine protease exhibiting antiangiogenic properties through proteolytic activity. KLK2 is overexpressed in prostate cancer and plays a pivotal role in cancer progression, establishing it as a potential therapeutic target.	

Assay Data

Bis-Tris PAGE




Human Kallikrein 2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Assay Data

Human Kallikrein 2, No Tag ELISA

0.05µg Human Kallikrein 2, No Tag Per Well



Immobilized Human Kallikrein 2, No Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Anti-Kallikrein 2 Antibody, hFc Tag with the EC50 of 3.3ng/ml determined by ELISA.

Bioactivity Data

Measured by its ability to cleave the fluorogenic peptide substrate: PFR-AMC. The specific activity is >450 pmol/min/µg.